Opendata, web and dolomites

Droplet Microarray SIGNED

Miniaturized System for Screening of Primary Cells based on Droplet Microarray

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Droplet Microarray project word cloud

Explore the words cloud of the Droplet Microarray project. It provides you a very rough idea of what is the project "Droplet Microarray" about.

replacing    personalized    slides    larger    incubator    mass    maximized    society    dispenser    dma    individual    circulating    life    business    possibility    impossible    optimal    clinical    employ    current    reagents    relevance    innovation    assays    microplates    direct    hardly    nano    read    apparatus    basic    performing    animal    alternative    revenues    liquid    technologies    2025    models    discovery    time    inevitably    throughput    companies    consumption    limits    mainly    plates    selling    model    context    extremely    precious    labcyte    medicine    b2b    stem    integrates    human    market    therapies    cartridge    nanoliter    ec    generate    medical    37    therapeutic    patient    aquarray    perform    healthy    reduce    disruptive    clinicians    experiments    screening    tests    screenings    miniaturization    precision    capturing    types    science    dispensers    dispendix    167m    scarcity    scarce    physiology    treatment    sales    cell    microtiter    drug    biological    tumor    cells    primary   

Project "Droplet Microarray" data sheet

The following table provides information about the project.

Coordinator
AQUARRAY GMBH 

Organization address
address: HERMANN-VON-HELMHOLTZ-PLATZ 1
city: EGGENSTEIN-LEOPOLDSHAFEN
postcode: 76344
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙499˙750 €
 EC max contribution 1˙749˙825 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUARRAY GMBH DE (EGGENSTEIN-LEOPOLDSHAFEN) coordinator 1˙749˙825.00

Map

 Project objective

Current cell screening systems based on microtiter plates are mainly used to perform drug discovery experiments. However, performing a larger number of therapeutic tests on patient derived (primary) cells is yet impossible due to the high consumption of reagents and cells when using microplates. In the clinical context, personalized drug screenings for optimal medical treatment are not possible due to the scarcity of precious primary cells. In pre-clinical drug discovery, the extremely high cost of primary cells limits the innovation potential as researchers hardly have access to screening models which are relevant for human physiology. The possibility to use scarce cell types like primary cells or stem cells therefore is the future of basic life science research, drug discovery (replacing animal models) as well as personalized medicine applications (individual precision therapies) and will have significant impact for a healthy society. Further miniaturization of current assays would inevitably allow the wide use of scarce cell types and at the same time reduce costs, increase throughput, and increase biological relevance of screening results. DMA allows researchers and clinicians to perform meaningful experiments with primary cells and circulating tumor cells – alternative technologies hardly work with low cell numbers. EC funding Phase 2 will allow Aquarray to mass produce its offer – the DMA Cartridge and also the disruptive Cell Screening System that integrates the DMA Cartridge with a nanoliter dispenser, an incubator and a read-out apparatus. Aquarray’s disruptive business model will employ a B2B direct sales of the DMA Slides and the Screening System, and at the same time sales can be maximized through partnerships with companies selling liquid nano-dispensers such as Dispendix and Labcyte. We are expected to generate €167M revenues by 2025 capturing 9.37% of the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DROPLET MICROARRAY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DROPLET MICROARRAY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More